COMP <GO>
RMD vs DXCM // NET PROFIT MARGIN
ResMed Inc. (NYSE) VS. DexCom Inc. (NASDAQ) • 15-METRIC TALLY: RMD 10
— DXCM 3
▲ NET PROFIT MARGIN LEADER: RMD
LAST: $252.83 (+1.06%) • MKT CAP: $35.56B
net-margins
27.20%
LAST: $79.93 (+1.67%) • MKT CAP: $30.16B
net-margins
17.90%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (RMD VS. DXCM)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | RMD | DXCM | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 59.40% | 60.10% | -0.70 | DXCM | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 22.90% | 21.60% | +1.30 | RMD | /roic <GO> |
| EV/EBITDA & P/E Valuation | 19.9x | 25.2x | -5.30 | RMD | /valuation <GO> |
| Free Cash Flow Yield | 4.67% | 3.57% | +1.10 | RMD | /fcf-yield <GO> |
| Operating Margin | 32.70% | 19.60% | +13.10 | RMD | /operating-margins <GO> |
| Net Profit Margin ACTIVE | 27.20% | 17.90% | +9.30 | RMD | /net-margins <GO> |
| Revenue Growth (YoY) | 9.80% | 15.60% | -5.80 | DXCM | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.87% | 0.00% | +0.87 | RMD | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 12.49 | 7.14 | +5.35 | RMD | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 9/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 60.1 | 41.8 | +18.30 | RMD | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.93 | 1.10 | -0.17 | DXCM | /macro-sensitivity <GO> |
| Forward P/E Multiple | 23.6x | 30.3x | -6.70 | RMD | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $35.56B | $30.16B | $5.40B | RMD | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | RMD REV | DXCM REV | RMD GROSS % | DXCM GROSS % | RMD FCF | DXCM FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $5.15B | $4.66B | 59.4% | 60.1% | $1.66B | $1.08B |
| FY 2024 | $4.69B | $4.03B | 56.7% | 60.5% | $1.30B | $630.7M |
| FY 2023 | $4.22B | $3.62B | — | — | $503.3M | $585.5M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
RMD // BETA 0.93
DXCM // BETA 1.10